Stock listing
Drugs Made In America Acquisition Corp.
Selected listing: DMAA · NASDAQ · USD · US
Drugs Made In America Acquisition Corp. (NASDAQ:DMAA), Finance. Latest release May 14, 2026: Drugs Made In America Acquisition Corp. 1Q 2026: Net income…
- Ticker
- NASDAQ:DMAA
- Asset type
- Stock
- Sector
- Finance
- Industry
- Financial Conglomerates
- Exchange
- NASDAQ
- Currency
- USD
About Drugs Made In America Acquisition Corp.
Drugs Made In America Acquisition Corp. (DMAA) is a public company focused on the pharmaceutical sector in the American market. DMAA aims to contribute to the domestic production of pharmaceuticals, aligning with trends towards local manufacturing.
Latest news from Drugs Made In America Acquisition Corp.
Drugs Made In America Acquisition Corp. 1Q 2026: Net income $1.97M, EPS $0.06— 10-Q Summary
May 14, 2026
Drugs Made In America Acquisition to Merge With Power Analytics Global in Deal Valued Up to $1 Billion
May 5, 2026
Drugs Made In America Acquisition 10-K: $0 revenue, $5.94M net income, ($0.28M) net loss
April 15, 2026
Drugs Made In America Acquisition Corp - Enters Loi For De-Spac With Power Analytics Global Corp - SEC Filing
April 8, 2026
Drugs Made In America Acquisition Secures $500,000 Financing; Issues $100,000 Interim Note
March 27, 2026
Research Drugs Made In America Acquisition Corp.
Drugs Made In America Acquisition Corp. company profile
View the public company page for Drugs Made In America Acquisition Corp. on 6ix.
Drugs Made In America Acquisition Corp. news
Read company news and market updates connected to Drugs Made In America Acquisition Corp..
Drugs Made In America Acquisition Corp. investor events
Find investor webinars, events, and replay context for Drugs Made In America Acquisition Corp..